No profile data available.
Bolt Biotherapeutics, Inc. (BOLT) is a healthcare company in the additional cancer treatment drugs industry, based in Redwood City, United States, with about 40 full-time employees.
It reported revenue of $7.70 million for fiscal year 2025, up 0.1% from fiscal year 2024, and net income of -$33.38 million. Its market capitalization was $10.19 million as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. 2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. ; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc.
Bolt Biotherapeutics reported $7.70 million in revenue for fiscal year 2025, up 0.1% from $7.69 million in fiscal year 2024.
$10.19 million as of December 4, 2025.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Intensity Therapeutics, Inc. (INTS), Lisata Therapeutics, Inc. (LSTA), Phio Pharmaceuticals Corp. (PHIO), Oncotelic Therapeutics, Inc. (OTLC).